Intellia Therapeutics, Inc. (0JBU.L)
USD 9.2
(6.36%)
USD 9.2
(6.36%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 551.56 Million USD | 8.09% |
| 2022 | 510.28 Million USD | 69.58% |
| 2021 | 300.9 Million USD | 54.64% |
| 2020 | 194.57 Million USD | 30.18% |
| 2019 | 149.47 Million USD | 23.22% |
| 2018 | 121.3 Million USD | 26.79% |
| 2017 | 95.67 Million USD | 96.7% |
| 2016 | 48.63 Million USD | 150.03% |
| 2015 | 19.45 Million USD | 53.77% |
| 2014 | 12.65 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 140.42 Million USD | 1.78% |
| 2024 Q2 | 143.4 Million USD | 2.12% |
| 2023 Q2 | 145.92 Million USD | 17.15% |
| 2023 FY | 551.56 Million USD | 8.09% |
| 2023 Q4 | 137.97 Million USD | -3.58% |
| 2023 Q1 | 124.56 Million USD | 0.73% |
| 2023 Q3 | 143.09 Million USD | -1.94% |
| 2022 Q1 | 155.49 Million USD | 66.72% |
| 2022 Q4 | 123.66 Million USD | 4.09% |
| 2022 Q3 | 118.79 Million USD | 5.76% |
| 2022 Q2 | 112.33 Million USD | -27.76% |
| 2022 FY | 510.28 Million USD | 69.58% |
| 2021 Q3 | 79.19 Million USD | 4.8% |
| 2021 Q4 | 93.26 Million USD | 17.77% |
| 2021 FY | 300.9 Million USD | 54.64% |
| 2021 Q1 | 52.87 Million USD | 7.91% |
| 2021 Q2 | 75.56 Million USD | 42.93% |
| 2020 Q4 | 48.99 Million USD | -2.64% |
| 2020 FY | 194.57 Million USD | 30.18% |
| 2020 Q1 | 45.96 Million USD | 12.91% |
| 2020 Q3 | 50.32 Million USD | 2.08% |
| 2020 Q2 | 49.29 Million USD | 7.25% |
| 2019 Q3 | 35.94 Million USD | -6.83% |
| 2019 FY | 149.47 Million USD | 23.22% |
| 2019 Q1 | 34.24 Million USD | 19.62% |
| 2019 Q4 | 40.7 Million USD | 13.25% |
| 2019 Q2 | 38.57 Million USD | 12.66% |
| 2018 Q4 | 28.62 Million USD | -9.14% |
| 2018 FY | 121.3 Million USD | 26.79% |
| 2018 Q3 | 31.5 Million USD | 0.75% |
| 2018 Q2 | 31.27 Million USD | 4.59% |
| 2018 Q1 | 29.89 Million USD | -4.73% |
| 2017 FY | 95.67 Million USD | 96.7% |
| 2017 Q3 | 23.19 Million USD | 5.74% |
| 2017 Q2 | 21.93 Million USD | 14.46% |
| 2017 Q4 | 31.38 Million USD | 35.32% |
| 2017 Q1 | 19.16 Million USD | 16.5% |
| 2016 FY | 48.63 Million USD | 150.03% |
| 2016 Q4 | 16.44 Million USD | 30.9% |
| 2016 Q3 | 12.56 Million USD | 12.68% |
| 2016 Q2 | 11.15 Million USD | 31.65% |
| 2016 Q1 | 8.47 Million USD | 17.91% |
| 2015 FY | 19.45 Million USD | 53.77% |
| 2015 Q3 | 4.98 Million USD | 3.96% |
| 2015 Q4 | 7.18 Million USD | 44.0% |
| 2015 Q1 | 2.48 Million USD | -56.79% |
| 2015 Q2 | 4.79 Million USD | 93.43% |
| 2014 FY | 12.65 Million USD | 0.0% |
| 2014 Q4 | 5.74 Million USD | 0.0% |
| 2014 Q2 | 166.99 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | -93.474% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -1037.203% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -4443.003% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -34.921% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -100.065% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -287.164% |
| Imunon, Inc. | 21.03 Million USD | -2522.704% |
| Dynavax Technologies Corporation | 219.14 Million USD | -151.69% |
| Editas Medicine, Inc. | 247.3 Million USD | -123.032% |
| FibroGen, Inc. | 398.11 Million USD | -38.545% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -22.3% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1308.745% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 65.452% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 59.468% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -4.264% |
| Verastem, Inc. | 92.08 Million USD | -498.981% |
| Zoetis Inc. | 2.76 Billion USD | 80.052% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 88.449% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -141.196% |
| Homology Medicines, Inc. | 9.87 Million USD | -5485.478% |
| Nektar Therapeutics | 190.9 Million USD | -188.925% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -447.042% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1134.84% |
| Perrigo Company plc | 1.52 Billion USD | 63.915% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -102.858% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.641% |
| Illumina, Inc. | 3.81 Billion USD | 85.535% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 94.621% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 73.134% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -357.136% |
| Waters Corporation | 943.51 Million USD | 41.541% |
| Biogen Inc. | 5.2 Billion USD | 89.403% |
| Evolus, Inc. | 189.75 Million USD | -190.667% |
| Adicet Bio, Inc. | 152.03 Million USD | -262.782% |
| bluebird bio, Inc. | 240.23 Million USD | -129.597% |
| Geron Corporation | 70.44 Million USD | -683.018% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 69.358% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -28.976% |
| Myriad Genetics, Inc. | 600.1 Million USD | 8.088% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 49.369% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -3865.35% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 68.415% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 80.408% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 73.921% |
| OPKO Health, Inc. | 574.68 Million USD | 4.023% |
| Exelixis, Inc. | 1.58 Billion USD | 65.24% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -49.633% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -889.25% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -15.788% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 29.249% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -84.274% |
| Blueprint Medicines Corporation | 722.86 Million USD | 23.697% |
| Insmed Incorporated | 949.26 Million USD | 41.895% |
| TG Therapeutics, Inc. | 198.47 Million USD | -177.902% |
| Incyte Corporation | 1.19 Billion USD | 53.669% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 47.168% |